The Epigenetic Downregulation of LncGHRLOS Mediated by RNA M6A Methylase ZCCHC4 Promotes Colorectal Cancer Tumorigenesis

Overview

Journal J Exp Clin Cancer Res

Publisher Biomed Central

Specialty Oncology

Date 2024 Feb 7

PMID 38326863

Authors

Ke Chen

Jingcheng Zhang

Lei Meng

Lingshang Kong

Ming Lu

Zhengguang Wang

Wenbin Wang

Affiliations

Soon will be listed here.

Abstract

Background: m6A modification is currently recognized as a major driver of RNA function that maintains cancer cell homeostasis. Long non-coding (Lnc) RNAs control cell proliferation and play an important role in the occurrence and progression of colorectal cancer (CRC). ZCCHC4 is a newly discovered m6A methyltransferase whose role and mechanism in tumors have not yet been elucidated.

Methods: The EpiQuik m6A RNA methylation kit was used to detect the level of total RNA m6A in six types of digestive tract tumors. The Kaplan-Meier method and receiver operating characteristic curve were used to evaluate the prognostic and diagnostic value of the newly discovered m6A methyltransferase, ZCCHC4, in CRC. The effects on CRC growth in vitro and in vivo were studied using gain- and loss-of-function experiments. The epigenetic mechanisms underlying ZCCHC4 upregulation in CRC were studied using RIP, MeRIP-seq, RNA pull-down, and animal experiments.

Results: We reported that the ZCCHC4-LncRNAGHRLOS-KDM5D axis regulates the growth of CRC in vitro and in vivo. We found that ZCCHC4 was upregulated in primary CRC samples and could predict adverse clinical outcomes in patients with CRC. Mechanistically, ZCCHC4 downregulated LncRNAGHRLOS to promote CRC tumorigenesis. As a downstream molecule of LncRNAGHRLOS, KDM5D directly controls CRC cell proliferation, migration, and invasion.

Conclusion: This study suggests that the ZCCHC4 axis contributes to the tumorigenesis and progression of CRC and that ZCCHC4 may be a potential biomarker for this malignancy.

Citing Articles

ZCCHC4 regulates esophageal cancer progression and cisplatin resistance through ROS/c-myc axis.

Yao L, Wu P, Yao F, Huang B, Zhong F, Wang X Sci Rep. 2025; 15(1):5149.

PMID: 39934309 PMC: 11814405. DOI: 10.1038/s41598-025-89628-3.

Epigenetic regulation in female reproduction: the impact of m6A on maternal-fetal health.

Li P, Lin Y, Ma H, Zhang J, Zhang Q, Yan R Cell Death Discov. 2025; 11(1):43.

PMID: 39904996 PMC: 11794895. DOI: 10.1038/s41420-025-02324-z.

Recent advances in noncoding RNA modifications of gastrointestinal cancer.

Hara T, Meng S, Arao Y, Saito Y, Inoue K, Rennie S Cancer Sci. 2024; 116(1):8-20.

PMID: 39487589 PMC: 11711047. DOI: 10.1111/cas.16380.

Correction: The epigenetic downregulation of LncGHRLOS mediated by RNA m6A methylase ZCCHC4 promotes colorectal cancer tumorigenesis.

Chen K, Zhang J, Meng L, Kong L, Lu M, Wang Z J Exp Clin Cancer Res. 2024; 43(1):78.

PMID: 38561777 PMC: 10986020. DOI: 10.1186/s13046-024-03005-y.

References

Deng X, Su R, Weng H, Huang H, Li Z, Chen J . RNA N-methyladenosine modification in cancers: current status and perspectives. Cell Res. 2018; 28(5):507-517. PMC: 5951805. DOI: 10.1038/s41422-018-0034-6. View

Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang L . A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol. 2013; 10(2):93-5. PMC: 3911877. DOI: 10.1038/nchembio.1432. View

Ping X, Sun B, Wang L, Xiao W, Yang X, Wang W . Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase. Cell Res. 2014; 24(2):177-89. PMC: 3915904. DOI: 10.1038/cr.2014.3. View

Li Z, Weng H, Su R, Weng X, Zuo Z, Li C . FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N-Methyladenosine RNA Demethylase. Cancer Cell. 2016; 31(1):127-141. PMC: 5234852. DOI: 10.1016/j.ccell.2016.11.017. View

Zheng G, Dahl J, Niu Y, Fedorcsak P, Huang C, Li C . ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Mol Cell. 2012; 49(1):18-29. PMC: 3646334. DOI: 10.1016/j.molcel.2012.10.015. View

Wang X, Lu Z, Gomez A, Hon G, Yue Y, Han D . N6-methyladenosine-dependent regulation of messenger RNA stability. Nature. 2013; 505(7481):117-20. PMC: 3877715. DOI: 10.1038/nature12730. View

Huang H, Weng H, Sun W, Qin X, Shi H, Wu H . Recognition of RNA N-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018; 20(3):285-295. PMC: 5826585. DOI: 10.1038/s41556-018-0045-z. View

Liu N, Dai Q, Zheng G, He C, Parisien M, Pan T . N(6)-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions. Nature. 2015; 518(7540):560-4. PMC: 4355918. DOI: 10.1038/nature14234. View

Wang X, Zhao B, Roundtree I, Lu Z, Han D, Ma H . N(6)-methyladenosine Modulates Messenger RNA Translation Efficiency. Cell. 2015; 161(6):1388-99. PMC: 4825696. DOI: 10.1016/j.cell.2015.05.014. View

10.

Geula S, Moshitch-Moshkovitz S, Dominissini D, AlFatah Mansour A, Kol N, Salmon-Divon M . Stem cells. m6A mRNA methylation facilitates resolution of naïve pluripotency toward differentiation. Science. 2015; 347(6225):1002-6. DOI: 10.1126/science.1261417. View

11.

Lin Z, Hsu P, Xing X, Fang J, Lu Z, Zou Q . Mettl3-/Mettl14-mediated mRNA N-methyladenosine modulates murine spermatogenesis. Cell Res. 2017; 27(10):1216-1230. PMC: 5630681. DOI: 10.1038/cr.2017.117. View

12.

Li H, Tong J, Zhu S, Batista P, Duffy E, Zhao J . mA mRNA methylation controls T cell homeostasis by targeting the IL-7/STAT5/SOCS pathways. Nature. 2017; 548(7667):338-342. PMC: 5729908. DOI: 10.1038/nature23450. View

13.

Zhang C, Chen Y, Sun B, Wang L, Yang Y, Ma D . mA modulates haematopoietic stem and progenitor cell specification. Nature. 2017; 549(7671):273-276. DOI: 10.1038/nature23883. View

14.

Li F, Yi Y, Miao Y, Long W, Long T, Chen S . N-Methyladenosine Modulates Nonsense-Mediated mRNA Decay in Human Glioblastoma. Cancer Res. 2019; 79(22):5785-5798. PMC: 7360104. DOI: 10.1158/0008-5472.CAN-18-2868. View

15.

Zhang C, Samanta D, Lu H, Bullen J, Zhang H, Chen I . Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m⁶A-demethylation of NANOG mRNA. Proc Natl Acad Sci U S A. 2016; 113(14):E2047-56. PMC: 4833258. DOI: 10.1073/pnas.1602883113. View

16.

Yue B, Song C, Yang L, Cui R, Cheng X, Zhang Z . METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer. Mol Cancer. 2019; 18(1):142. PMC: 6790244. DOI: 10.1186/s12943-019-1065-4. View

17.

Wu Y, Yang X, Chen Z, Tian L, Jiang G, Chen F . mA-induced lncRNA RP11 triggers the dissemination of colorectal cancer cells via upregulation of Zeb1. Mol Cancer. 2019; 18(1):87. PMC: 6461827. DOI: 10.1186/s12943-019-1014-2. View

18.

Menon N, Patil V, Noronha V, Joshi A, Bhattacharjee A, Satam B . Quality of life in patients with locally advanced head and neck cancer treated with concurrent chemoradiation with cisplatin and nimotuzumab versus cisplatin alone - Additional data from a phase 3 trial. Oral Oncol. 2021; 122:105517. DOI: 10.1016/j.oraloncology.2021.105517. View

19.

Borden E . Interferons α and β in cancer: therapeutic opportunities from new insights. Nat Rev Drug Discov. 2019; 18(3):219-234. DOI: 10.1038/s41573-018-0011-2. View

20.

Ma H, Jin S, Yang W, Zhou G, Zhao M, Fang S . Interferon-alpha enhances the antitumour activity of EGFR-targeted therapies by upregulating RIG-I in head and neck squamous cell carcinoma. Br J Cancer. 2018; 118(4):509-521. PMC: 5830595. DOI: 10.1038/bjc.2017.442. View